Psych CASC / OSCE · Addiction psychiatry
Explaining anti-craving medicines after detox — CASC communication station
MRCPsych/FRANZCP-style communication station: explain naltrexone, acamprosate, and disulfiram in plain language with doses and safety gates; address opioids, liver concerns, disulfiram alcohol education, COMBINE-level honesty about expectations, and psychosocial aftercare.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes after reading time. You are the psychiatry registrar in the post-detox clinic. [5]
Candidate instructions. Explain that medicines reduce risk of relapse but are not a permanent cure; outline naltrexone, acamprosate, and disulfiram in plain language with key doses and safety points; address leftover opioids before naltrexone; address liver monitoring without catastrophising mild risk; correct the 'skip tablet then drink' plan for disulfiram; emphasise counselling/psychosocial care; shared decision and follow-up. [1][2][3]
Candidate scenario
Patient: “Just give me the strongest one.” Partner: “If she drinks champagne once, will her heart stop?” Oxycodone bottle is still in her handbag. [1][5]
Marking domains
- Empathy, non-stigmatising language, agenda setting
- Accurate phase-of-care explanation (detox done; now relapse prevention)
- Naltrexone: often one 50 mg tablet daily; not while opioids remain; LFT monitoring explained calmly
- Acamprosate: typically 666 mg three times daily; kidney check; helps stay off alcohol after detox
- Disulfiram: supervised; reaction if alcohol drunk; not for planned wedding sips; education about hidden alcohol
- Honest expectations (helps many people, not magic cure); psychosocial care essential
- Shared decision, teach-back, follow-up and crisis plan
Reveal assessor key
Open. Introduce role; acknowledge anxiety about craving and liver; involve partner with consent. [5]
Frame medicines. After detox, tablets or monthly injections can make relapse less likely by reducing the reward of drinking (naltrexone), supporting the brain’s balance in early sobriety (acamprosate), or causing a strong unpleasant reaction if alcohol is drunk (disulfiram). None is a forever cure; all work best with talking therapies and support.[1][2][4]
Opioid gate. Leftover oxycodone must be disposed/planned carefully; naltrexone must not start until opioids are fully stopped for a safe interval — otherwise severe withdrawal and pain medicines will not work as expected. Offer medical alert advice.[1]
Doses in plain language. Naltrexone often one 50 mg tablet daily (or monthly injection where available); acamprosate often 666 mg three times a day after kidney check; disulfiram often 200–250 mg daily only if she and a supervisor understand the alcohol reaction rules.[1][2][3]
Wedding / skip-dose myth. Skipping disulfiram to drink is unsafe and defeats the treatment contract; even small alcohol exposures can trigger reactions. If she is not ready for that commitment, choose another medicine.[3]
Liver. We check blood tests and avoid careless starts in severe liver failure; many people with milder enzyme changes still use medicines with monitoring — individualise.[1][5]
Close. Agree preferred option after opioid clearance; book early review; written information; partner supervision plan if disulfiram chosen; crisis contacts. Teach-back. [1][5]
References
- [1]Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder Am J Psychiatry, 2018.PMID 29301420
- [2]Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis JAMA, 2014.PMID 24825644
- [3]Fuller RK, Gordis E Does disulfiram have a role in alcoholism treatment today? Addiction, 2004.PMID 14678055
- [4]Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial JAMA, 2006.PMID 16670409
- [5]Connor JP, Haber PS, Hall WD Alcohol use disorders Lancet, 2016.PMID 26343838